Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 319 Cr.
- Current Price ₹ 229
- High / Low ₹ 316 / 70.8
- Stock P/E 33.6
- Book Value ₹ 38.8
- Dividend Yield 0.00 %
- ROCE 35.9 %
- ROE 53.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 54.6%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 60.9 days to 88.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|
39 | 71 | 99 | 114 | |
36 | 66 | 89 | 98 | |
Operating Profit | 2 | 5 | 10 | 16 |
OPM % | 6% | 7% | 10% | 14% |
1 | 1 | 1 | 1 | |
Interest | 1 | 1 | 2 | 3 |
Depreciation | 1 | 1 | 1 | 1 |
Profit before tax | 1 | 4 | 9 | 13 |
Tax % | 30% | 28% | 23% | 24% |
1 | 3 | 7 | 10 | |
EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 43% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 123% |
TTM: | 55% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 55% |
Last Year: | 53% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|
Equity Capital | 1 | 1 | 1 | 5 | 14 |
Reserves | 3 | 6 | 12 | 17 | 40 |
9 | 11 | 23 | 29 | 0 | |
9 | 17 | 23 | 19 | 48 | |
Total Liabilities | 22 | 34 | 59 | 71 | 102 |
4 | 5 | 4 | 19 | 19 | |
CWIP | 0 | 4 | 8 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 |
18 | 26 | 46 | 52 | 83 | |
Total Assets | 22 | 34 | 59 | 71 | 102 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|
3 | 7 | 12 | 9 | |
-1 | -5 | -7 | -5 | |
-1 | -1 | -2 | -3 | |
Net Cash Flow | 1 | 1 | 3 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|
Debtor Days | 75 | 59 | 57 | 49 |
Inventory Days | 84 | 62 | 78 | 89 |
Days Payable | 82 | 79 | 56 | 31 |
Cash Conversion Cycle | 76 | 43 | 78 | 108 |
Working Capital Days | 76 | 36 | 58 | 89 |
ROCE % | 32% | 38% | 36% |
Documents
Announcements
- Trading Window 27 March 2024
- Analysts/Institutional Investor Meet/Con. Call Updates 13 March 2024
- Analysts/Institutional Investor Meet/Con. Call Updates 8 March 2024
- Analysts/Institutional Investor Meet/Con. Call Updates 29 February 2024
- Analysts/Institutional Investor Meet/Con. Call Updates 27 February 2024
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis